cmAngio® vs AVIEW Lung Nodule CAD
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography data for early cardiovascular risk assessment in women. This tool is specifically designed to detect Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing valuable insights into cardiovascular health without additional radiation or procedures. It's ideal for integrating cardiovascular risk screening into routine breast imaging workflows.
View cmAngio® →Choose AVIEW Lung Nodule CAD if…
Choose AVIEW Lung Nodule CAD if you require a comprehensive AI solution for analyzing chest CT scans, encompassing lung cancer screening, COPD assessment, and coronary artery calcification scoring. This tool excels at detecting and quantifying pulmonary nodules, generating Lung-RADS reports, and simultaneously evaluating emphysema and CAC, making it suitable for a broad thoracic health assessment from a single CT study.
View AVIEW Lung Nodule CAD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | AVIEW Lung Nodule CAD |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | On-premises and cloud environment |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae emphasizes quick and easy installation (less than an hour) and compatibility with any DICOM-compliant viewer, streamlining integration into existing radiology workflows. While AVIEW Lung Nodule CAD offers automated reporting, cmAngio's focus on rapid setup and seamless viewer compatibility provides a stronger initial usability advantage for busy clinical environments.
Clinical Value
AVIEW Lung Nodule CADAVIEW Lung Nodule CAD offers a comprehensive 'Big 3' analysis from a single CT scan, simultaneously assessing lung nodules, emphysema, and coronary artery calcification (CAC scoring). This integrated approach provides broader clinical utility and a more holistic patient assessment compared to cmAngiou00ae's focus on breast arterial calcifications for cardiovascular risk.
Pricing & Value
TieBoth tools require direct contact for pricing details, making a direct comparison of their cost-effectiveness impossible. While cmAngiou00ae mentions potential 'limited-time offers for no-cost implementation and service,' these are not guaranteed or publicly detailed, preventing a clear winner in this dimension.
Enterprise Readiness
AVIEW Lung Nodule CADBoth tools are FDA-cleared and HIPAA-compliant, establishing a baseline for enterprise readiness. However, AVIEW Lung Nodule CAD offers a wider array of deployment options, including cloud-based, hybrid, and local (dedicated hardware, virtualized), providing greater flexibility for integration into diverse enterprise IT infrastructures and security policies.
Innovation
cmAngio®cmAngiou00ae demonstrates a unique innovation by repurposing existing mammography data to identify breast arterial calcifications for cardiovascular risk assessment, offering a non-invasive, opportunistic screening method without additional radiation or procedures. This approach extracts new, significant clinical value from a routinely performed exam.
Support & Docs
TieNeither the provided structured facts nor web searches yielded specific, detailed information regarding public documentation portals, service level agreements, or comprehensive support plans for either product. Both companies' websites mention general customer support and contact options, but lack the granularity needed for a comparative assessment.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | AVIEW Lung Nodule CAD |
|---|---|---|
| Product Name | cmAngiou00ae | AVIEW Lung Nodule CAD |
| Company | CureMetrix | Coreline Soft Co. |
| Primary Detection Target | Breast Arterial Calcifications (BAC) on mammograms (FFDM and DBT exams) | Pulmonary nodules (3-20 mm) on chest CT scans |
| Supported Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Pulmonology, Radiology |
| Key Analysis/Quantification | Visualization of BAC location on a scorecard | Nodule classification (solid, part-solid, non-solid), 3D nodule size and volume quantification, Nodule matching and volume doubling time (VDT) calculation |
| Additional Screening Capabilities | Provides insights into cardiovascular health | Simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3), Quantitative emphysema analysis, Coronary Artery Calcification (CAC) scoring |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and AVIEW Lung Nodule CAD.